dc.contributor.author | Kaplan, Necati | |
dc.contributor.author | Yılmaz, İbrahim | |
dc.contributor.author | Karaarslan, Numan | |
dc.contributor.author | Kaya, Yasin Emre | |
dc.contributor.author | Yaşar, Şirin, Duygu | |
dc.contributor.author | Özbek, Hanefi | |
dc.date.accessioned | 2019-12-25T20:25:46Z | |
dc.date.available | 2019-12-25T20:25:46Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Kaplan, N., Yılmaz, İ., Karaarslan, N., Kaya, Y. E., Şirin, D. Y. ve Özbek, H. (2019). Does nimodipine, a selective calcium channel blocker, impair chondrocyte proliferation or damage extracellular matrix structures? Current Pharmaceutical Biotechnology. 20(6), 517-524. https://doi.org/10.2174/1389201020666190506124548 | en_US |
dc.identifier.issn | 1389-2010 | |
dc.identifier.issn | 1873-4316 | |
dc.identifier.uri | https://doi.org/10.2174/1389201020666190506124548 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4702 | |
dc.description.abstract | Background: The study aimed to investigate the effects of the active ingredient, nimodipine, on chondrocyte proliferation and extracellular matrix (ECM) structures in cartilage tissue cells. Methods: Chondrocyte cultures were prepared from tissues resected via surgical operations. Nimodipine was then applied to these cultures and molecular analysis was performed. The data obtained were statistically calculated. Results: Both, the results of the (3-(4,5 dimethylthiazol2-yl)-2,5-diphenyltetrazolium (MTT) assay and the fluorescence microscope analysis [a membrane permeability test carried out with acridine orange/propidium iodide staining (AO/PI)] confirmed that the active ingredient, nimodipine, negatively affects the cell cultures. Conclusion: Nimodipine was reported to suppress cellular proliferation; chondroadherin (CHAD) and hypoxia-inducible factor-1 alpha (HIF-1α) expression thus decreased by 2.4 and 1.7 times, respectively, at 24 hrs when compared to the control group (p < 0.05). Furthermore, type II collagen (COL2A1) expression was not detected (p < 0.05). The risk that a drug prescribed by a clinician in an innocuous manner to treat a patient by relieving the symptoms of a disease may affect the proliferation, differentiation, and viability of other cells and/or tissues at the molecular level, beyond its known side effects or adverse events, should not be forgotten. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Bentham Science Publishers | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Chondroadherin | en_US |
dc.subject | Chondrocyte | en_US |
dc.subject | Hypoxia-Inducible Factor-1 Alpha | en_US |
dc.subject | Nimodipine | en_US |
dc.subject | Type II Collagen | en_US |
dc.subject | Matrix Structures | en_US |
dc.title | Does nimodipine, a selective calcium channel blocker, impair chondrocyte proliferation or damage extracellular matrix structures? | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Current Pharmaceutical Biotechnology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-2003-6337 | en_US |
dc.authorid | 0000-0002-8084-7855 | en_US |
dc.identifier.volume | 20 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.startpage | 517 | en_US |
dc.identifier.endpage | 524 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.2174/1389201020666190506124548 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |